FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
Leerink Partners analyst Jonathan Chang raised the price target on Zai Lab (NASDAQ: ZLAB) to $75.00 (from $73.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: ZLAB partner AMGN (MP, Risinger) announced today that the Phase III FORTITUDE-101 study evaluating bemarituzumab in combination with chemotherapy in 1L FGFR2b+... More

